BioPharm International
October 02, 2010
Issue PDF
2010 Supplement
8
The Evolution of Vaccines
October 02, 2010
Peer-Reviewed Research
2010 Supplement
8
Release testing involves both standard potency assays and unique assays (particle size, NA activity) developed to ensure the physical, chemical, and biological stability of this type of vaccine.
October 02, 2010
Peer-Reviewed Research
2010 Supplement
8
Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).
October 02, 2010
Peer-Reviewed Research
2010 Supplement
8
Filterability and bacterial retention must be verified very early in process development to ensure successful sterilizing filtration validation.
October 02, 2010
Peer-Reviewed Research
2010 Supplement
8
Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).